Every Form 4 that Bio-Techne Corp (TECH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TECH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TECH filings page.
BIO-TECHNE Corp (TECH) reported that officer Shane Bohnen, SVP – General Counsel, received two equity awards on 2026-08-17: 11,344 Restricted Stock Units that vest in three annual installments from 2027–2029, and 18,432 Restricted Stock Units that vest on 2029-08-17. Each unit represents a contingent right to one share of common stock. Bohnen also reports direct holdings of 10,360 common shares and multiple outstanding stock options and performance RSUs with various exercise prices and vesting schedules.
BIO-TECHNE Corp (TECH) reported that its Chief Executive Officer, Kim Kelderman, received equity awards of 57,590 and 93,582 restricted stock units on August 17, 2026. Each unit represents one share of BIO-TECHNE common stock.
The 57,590 RSUs vest in three installments of 19,197, 19,197, and 19,196 units on August 17, 2027, 2028, and 2029. The 93,582 RSUs vest on August 17, 2029. Separately, Kelderman directly holds 82,762 BIO-TECHNE common shares and multiple stock option grants, including options over 115,724 shares at an exercise price of $66.97 expiring August 5, 2027.
BIO-TECHNE Corp (TECH) reported that CFO James Hippel received two equity awards on 2026-08-17: grants of 22,438 Restricted Stock Units and 36,459 Restricted Stock Units, each representing a contingent right to one share of common stock. According to the vesting footnotes, 7,479 RSUs vest on each of 8/17/2027 and 8/17/2028, and 7,480 vest on 8/17/2029 for the first award, while the second award of 36,459 RSUs vests on 8/17/2029. Hippel also holds multiple stock option positions on BIO-TECHNE common stock with exercise prices between $53.60 and $120.46 and expirations from 2027 through 2035, and directly holds 170,183 shares of common stock.
BIO-TECHNE Corp (TECH) director Amy E. Herr reported an indirect grant of 1,381 Restricted Stock Units on 2026-08-17, held through a significant other. Each unit represents a contingent right to receive one share of BIO-TECHNE common stock, vesting in three annual installments in 2027, 2028, and 2029.
The filing also lists existing option and RSU awards with various exercise prices from $53.60 to $120.46 and expiration dates through 2035, along with direct holdings of 2,680 common shares and 576 indirect common shares. No sales or option exercises are reported.
BIO-TECHNE Corp (symbol: TECH) is the issuer of record for a Form 4 filing submitted to the SEC.
BIO-TECHNE Corp (TECH) reported that its President - Diag & Spatial Bi, Steven C. Crouse, received equity awards on August 17, 2026. He was granted 8,702 restricted stock units and a separate award of 14,140 restricted stock units, each representing a right to one share of common stock, with multi-year vesting schedules through 2029. Following these awards, he directly holds 10,237 shares of common stock and maintains multiple stock option positions on BIO-TECHNE common stock with exercise prices ranging from $48.61 to $120.46 and expirations between 2028 and 2036.
BIO-TECHNE Corp (TECH) reports that Chief Executive Officer Kim Kelderman had multiple equity award updates on 8/15/2026. Several performance restricted stock units and options were exercised or converted into common stock, and other performance-based awards were disposed of to the issuer or forfeited following Board actions on discretionary vesting. Kelderman acquired 21,470 shares of common stock through exercises, while 10,821 shares of common stock were delivered or withheld to cover exercise price or tax liability. Footnotes state the Board authorized discretionary vesting for specified tranches of performance RSUs and options, with remaining portions forfeited, and that Kelderman continues to hold multiple stock option grants and performance RSUs covering substantial numbers of underlying BIO-TECHNE common shares.
BIO-TECHNE Corp (TECH) CFO James Hippel reported multiple equity-award transactions on 8/15/2026. He acquired 9,779 shares of common stock through exercises or conversions of restricted stock units, and 4,310 shares of common stock were delivered or withheld at $72.40 per share for payment of exercise price or tax liability. The board authorized discretionary vesting of 866 performance RSUs and 2,332 performance options, with the remaining related performance awards forfeited. Hippel continues to hold several option and RSU awards over BIO-TECHNE common stock with exercise prices ranging from $53.60 to $120.46 and expirations extending to 2035-08-15.
BIO-TECHNE Corp (TECH) reports that officer William Geist had several equity award updates on 8/15/2026. He acquired 6,416 shares of common stock through the vesting and conversion of restricted stock units and performance RSUs/options, while 1,976 shares of common stock were delivered or withheld at $72.40 per share to cover exercise price or tax liability. The Board authorized discretionary vesting of 567 performance RSUs and 1,526 performance options, with the remaining performance RSUs and options from those grants forfeited and reported as dispositions to the issuer. Geist continues to hold multiple option grants and performance RSUs with future vesting and performance-based vesting dates out to 2035.
BIO-TECHNE Corp (TECH) reported that officer Shane Bohnen, SVP – General Counsel, had multiple equity award events on 2026-08-15. Awards of restricted stock units and performance restricted stock units were converted into 4,350 shares of Common Stock, with 1,343 shares delivered or withheld for payment of exercise price or tax liability. The Board authorized discretionary vesting of 807 performance stock options and 300 performance RSUs, while the remaining related performance options and performance RSUs were forfeited and disposed to the issuer. Bohnen continues to hold several stock option grants on BIO-TECHNE Common Stock with exercise prices ranging from $53.60 to $120.46 and expiration dates between 2027 and 2035, as well as unvested performance RSUs. The transactions were not reported as made under a Rule 10b5-1 trading plan.
BIO-TECHNE Corp (TECH) reported insider equity activity by executive Steven C. Crouse, President - Diag & Spatial Bi. On 2026-08-15, Crouse exercised or converted restricted stock units into 5,423 shares of common stock, with no exercise price shown.
In connection with this, 1,947 common shares were disposed of at $72.40 per share for payment of exercise price or tax liability by delivering or withholding securities. Several equity awards and stock options remain outstanding, including multiple option grants with exercise prices between the mid-$40s and low-$120s and expirations from 2028 through 2036.
BIO-TECHNE Corp (TECH) director Amy E. Herr reported indirect equity compensation activity relating to her significant other. On 2026-08-15, 589 restricted stock units covering an equal number of common shares were exercised at $0.00 per share, and 213 common shares were delivered or withheld to cover exercise price or tax liability at $72.40 per share. Following these transactions, she holds 2,680 shares of BIO-TECHNE common stock directly and multiple stock option awards, including options over 2,415 shares at $72.05 expiring in 2035 and 3,777 shares at $60.96 expiring in 2035, along with additional indirect option and RSU positions that vest on various future dates.
Bio-Techne Corp CFO James Hippel exercised stock options covering 62,068 shares of common stock on July 29, 2026 at an exercise price of $47.60 per share. A separate Form 4 entry shows 51,024 shares of common stock disposed of at $72.03 per share, designated as payment of exercise price or tax liability by withholding securities. He continues to hold multiple option and restricted stock unit awards, including options over 167,328 shares at an exercise price of $66.97 expiring August 5, 2027.
Bio-Techne Corp CEO Kim Kelderman exercised stock options for 35,000 shares of common stock at an exercise price of $47.60 per share on 2026-07-28. He acquired these shares directly and had 28,686 shares of common stock withheld at $72.07 per share to pay the option exercise price or related tax liabilities. He continues to hold multiple stock option and restricted stock unit awards with various exercise prices, vesting dates and expirations.
Bio-Techne Corp SVP and General Counsel Shane Bohnen exercised stock options for 448 shares of common stock on 2026-07-23 at an exercise price of 47.6000 per share, converting an option on 448 shares into directly held stock. To satisfy the exercise price or related tax obligations, 344 shares of common stock were withheld at 71.7700 per share. He continues to hold multiple option and stock-unit awards, including stock options over 8,944 shares at a 66.9700 exercise price expiring 2027-08-05 and 3,460 shares at 120.4600 expiring 2028-08-06. The filing indicates these transactions were not made under a Rule 10b5-1 trading plan.
BIO-TECHNE Corp executive Steven C. Crouse reported routine equity compensation activity and updated holdings. On June 2, 2026, he exercised 600 restricted stock units into an equal number of common shares and had 216 shares of common stock withheld at $49.77 per share to satisfy tax obligations. Following the tax withholding, he directly held 6,761 shares of common stock. The filing also lists multiple outstanding stock options and restricted stock unit awards with exercise prices between $48.61 and $120.46 per share and expirations through 2036, indicating a substantial remaining equity position. A footnote states that a mathematical error in a prior Form 4 increased the reported beneficial ownership by 40 shares, and this filing reflects the corrected total.
BIO-TECHNE Corp director Amy E. Herr reported an exercise-and-sale transaction carried out through an account held by her significant other. On May 8, 2026, that account exercised 6,636 shares of BIO-TECHNE common stock at an exercise price of $47.60 per share and received the underlying shares.
On the same date, the same account sold 6,636 shares of common stock at a weighted average price of about $48.28 per share, leaving 200 indirect shares of common stock held by the significant other. Separately, Herr holds 2,680 shares of common stock directly, along with a range of stock options and restricted stock units that continue to represent additional exposure to BIO-TECHNE stock.
BIO-TECHNE Corp CFO James Hippel reported compensation-related equity activity. On May 5, 2026, he exercised 62,000 shares of stock options into common stock at an exercise price of $47.60 per share, converting a derivative award into direct share ownership.
On the same date, 56,955 shares of common stock were disposed of in a tax-withholding transaction at $56.68 per share, covering exercise price or tax obligations rather than representing an open-market sale. Following the exercise, his direct common stock holdings were 210,625 shares, and after tax withholding they were 153,670 shares, while he retained a substantial portfolio of unexercised options and restricted stock units.
BIO-TECHNE Corp senior vice president and general counsel Shane Bohnen reported routine equity compensation activity. On May 5, 2026, he exercised stock options to acquire 8,400 shares of common stock at an exercise price of $47.60 per share.
On the same date, 7,055 shares of common stock were disposed of at $56.68 per share to satisfy tax obligations, a tax-withholding disposition rather than an open-market sale. Following these transactions, Bohnen directly owned 7,249 shares of BIO-TECHNE common stock, and continued to hold a substantial package of unexercised options and restricted stock units that vest over several future dates.
Bio-Techne Corp Chief Executive Officer Kim Kelderman exercised stock options for 26,692 shares of common stock on May 5, 2026. The options had an exercise price of $47.60 per share, resulting in the acquisition of 26,692 common shares. On the same date, 23,951 common shares were delivered to satisfy tax obligations at $56.68 per share. After these transactions, Kelderman directly holds 65,799 common shares, 176,668 Stock Option (Right to Buy) awards, 307,975 additional Stock Options (Right to Buy), 49,826 Performance Stock Options, 140,265 Performance Restricted Stock Units, and 52,441 Restricted Stock Units.
Bio-Techne Corp executive Steven C. Crouse reported routine equity compensation activity involving company stock. On May 1, 2026, he exercised 794 Restricted Stock Units, which converted into an equal number of Bio-Techne common shares.
To cover tax obligations, 311 common shares were disposed of through a tax-withholding transaction, a non-market event that does not represent an open-market sale. Following these transactions, Crouse directly holds 6,688 shares of common stock, alongside multiple option and restricted stock unit awards that vest over several future dates.
Bio-Techne Corp Chief Executive Officer Kim Kelderman reported compensation-related equity activity, not open-market trading. On April 22, 2026, Kelderman exercised stock options to acquire 11,344 shares of Bio-Techne common stock, while 1,363 shares were disposed of to cover tax obligations at $58.58 per share. This left Kelderman with 63,058 common shares held directly after these transactions.
The filing also lists substantial remaining equity incentives, including multiple tranches of stock options and restricted stock units tied to vesting schedules and performance goals, with option exercise prices ranging from $47.60 to $120.46 and expirations extending to August 15, 2035.
Bio-Techne Corporation CFO James Hippel reported routine equity compensation activity. On April 22, 2026, he exercised stock options to acquire 62,000 shares of common stock at an exercise price of $47.60 per share. In a related F-code tax-withholding disposition, 56,097 shares of common stock were delivered at $58.58 per share to cover obligations. Following these transactions, Hippel directly owned 148,625 Bio-Techne common shares and retained substantial unexercised stock options and restricted stock units with vesting schedules extending through 2028.
Bio-Techne Corp Chief Executive Officer Kim Kelderman exercised stock options for 36,500 shares of common stock at an exercise price of $47.60 per share. The options were fully exercisable and converted into an equal number of common shares.
To cover tax obligations tied to this transaction, 32,088 shares of common stock were withheld at a price of $58.66 per share, a non-market tax-withholding disposition. After these transactions, Kelderman directly owns 53,077 common shares and retains substantial unexercised stock options and restricted stock units that vest over multiple future dates.
Bio-Techne Corp senior vice president and general counsel Shane Bohnen reported routine equity compensation activity. On April 3, 2026, he exercised restricted stock units into 2,259 shares of common stock. Of these, 740 shares were withheld at $53.13 per share to cover tax obligations, leaving him with 5,904 common shares held directly. He also continues to hold multiple stock option and restricted stock unit awards that can convert into additional Bio-Techne common shares over time.
Crouse Steven C. reported acquisition or exercise transactions in this Form 4 filing.
BIO-TECHNE Corp executive Steven C. Crouse reported new equity awards. On March 2, 2026, he received grants of 2,387 Performance Restricted Stock Units, 735 Restricted Stock Units, and 1,911 stock options, all held directly. Each restricted stock unit represents a contingent right to receive one share of BIO-TECHNE common stock, with various vesting dates extending through 2029 tied to service and, for the performance units, achievement of specified goals.
Bio-Techne Corp director Amy E. Herr reported an indirect sale of common stock through her significant other. On February 17, 2026, an account held by her significant other sold 1,976 shares of Bio-Techne common stock in an open-market transaction at a weighted average price of $59.105 per share, with individual trade prices ranging from $59.091 to $59.139.
After this sale, that indirect account held 200 shares of common stock. Separately, Herr holds 2,680 shares of common stock directly, along with various stock options and restricted stock units that vest on scheduled dates between 2025 and 2029, providing additional potential future equity exposure.
Bio-Techne director Amy E. Herr reported routine equity activity on 02/03/2026, mainly involving awards held by her significant other. On that date, 38 restricted stock units converted into 38 shares of common stock at $0, all held indirectly through her significant other.
To cover withholding obligations, 16 indirectly held common shares were disposed of at $64.63 per share, leaving 2,176 common shares indirectly held by her significant other and 2,680 shares held directly. The filing also lists multiple stock options and additional restricted stock units with vesting dates from 2026 through 2035, all either directly held or indirectly held through her significant other.
Bio-Techne Corp President – Diag & Spatial Bio, Matthew McManus, reported equity award activity in company stock. On February 1, 2026, 4,621 restricted stock units converted into the same number of common shares at $0 per share. On the same date, 1,665 common shares were withheld at $64.09 per share to cover obligations, leaving 7,691 common shares held directly.
McManus continues to hold multiple equity awards, including performance restricted stock units and stock options that vest over several future dates and run through expiration dates up to August 15, 2035. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
Bio‑Techne (TECH) Chief Executive Officer and Director Kim Kelderman reported an insider transaction. On 11/03/2025, he disposed of 2,303 shares of common stock at $62.57 under transaction code F, and now directly holds 48,665 shares.
The filing also lists multiple derivative awards outstanding, including stock options and restricted stock units. Examples include stock options covering 90,441 shares at an exercise price of $53.60 expiring on 08/15/2035, and performance RSUs covering 70,708 shares subject to performance-based vesting.
Bio-Techne (TECH) reported insider transactions by its CFO on 11/03/2025. The executive acquired company stock through RSU vesting and surrendered shares to cover taxes.
Two RSU conversions (code M) added 13,159 shares and 11,545 shares at $0. A tax withholding transaction (code F) disposed of 11,865 shares at $62.57. Following these transactions, the CFO directly owned 142,722 shares.
These actions reflect routine equity award vesting and associated tax settlement rather than an open‑market purchase or sale.
Bio‑Techne (TECH) reported an insider equity event by its President, Protein Sciences. On 11/03/2025, 9,911 shares were acquired at $0 upon settlement of restricted stock units, followed by the disposition of 4,520 shares at $62.57, typically associated with tax withholding. After these transactions, the officer directly owned 20,503 common shares.
The filing also lists outstanding equity awards, including stock options with expirations through 2035 and various time- and performance-based RSUs, indicating future vesting schedules tied to service and performance conditions.
Bio-Techne Corp (TECH) reported an insider equity transaction by a director. On 10/30/2025, the reporting person acquired 1,640 shares of common stock at $0 and received a grant of stock options for 3,777 shares at an exercise price of $60.96, expiring on 10/30/2035.
After these transactions, the director directly beneficially owns 8,775 shares of common stock. The option grant vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
Bio‑Techne (TECH) director reported equity changes on 10/30/2025. The filing shows an acquisition of 1,640 shares of Common Stock at $0, bringing direct holdings to 15,411 shares. It also reports a new grant of 3,777 stock options with an exercise price of $60.96 and an expiration on 10/30/2035. According to the note, this option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders.
Bio-Techne (TECH) director John L. Higgins filed a Form 4 reporting equity awards dated 10/30/2025. He acquired 1,640 shares of common stock at $0, bringing his directly held common stock to 66,876 shares after the transaction. He was also granted stock options for 3,777 shares with an exercise price of $60.96, expiring on 10/30/2035. The options vest on the earlier of the one‑year anniversary of the grant date or Bio‑Techne’s 2026 annual meeting of shareholders.
Bio-Techne (TECH) director Alpna Seth reported insider transactions. On 10/30/2025, she acquired 1,640 shares of common stock at $0, bringing her direct holdings to 15,411 shares. She also received a new stock option grant for 3,777 shares at an exercise price of $60.96, expiring on 10/30/2035. The option vests on the earlier of the one-year anniversary of the grant date or the company’s 2026 annual meeting of shareholders.
Bio‑Techne (TECH): Form 4 insider update. Director Amy E. Herr reported an equity grant on 10/30/2025. She acquired 1,640 shares of common stock at $0, bringing direct holdings to 2,680 shares; an additional 2,154 shares are held indirectly by a significant other.
She was also granted a stock option to buy 3,777 shares at $60.96, expiring 10/30/2035; vesting occurs on the earlier of the one‑year anniversary of the grant or the 2026 annual meeting. The filing also lists previously awarded options and restricted stock units held indirectly with specified vesting schedules.
Bio‑Techne (TECH) director Judith V. Klimovsky filed a Form 4 reporting equity awards. On 10/30/2025, she acquired 1,640 shares of common stock at $0, bringing direct holdings to 3,782 shares.
She was also granted a stock option for 3,777 shares at an exercise price of $60.96, expiring 10/30/2035. The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders. Existing options include 1,610 at $73.46 (exp. 05/01/2034) and 3,511 at $68.37 (exp. 10/24/2034).
Bio‑Techne (TECH) reported an insider equity update. A director acquired 1,640 shares of common stock on 10/30/2025 at a reported price of $0, bringing direct beneficial ownership to 10,987 shares after the transaction.
The filing also lists a new derivative award: 3,777 stock options acquired on 10/30/2025 with an exercise price of $60.96 and an expiration date of 10/30/2035. According to the footnote, the option vests on the earlier of the one‑year anniversary of the grant date (10/30/2025) or the date of Bio‑Techne’s 2026 annual meeting of shareholders.
Bio‑Techne (TECH) director Robert V. Baumgartner reported insider activity. On 10/30/2025, he acquired 1,640 common shares at $0, bringing his directly held shares to 46,503 after the transaction. He was also granted a stock option for 3,777 shares at an exercise price of $60.96, expiring on 10/30/2035. The option vests on the earlier of the one‑year anniversary of the grant date or the company’s 2026 annual meeting of shareholders.